Member Info for Ollieh

Https://finance.yahoo.com/markets/stocks/articles/summit-therapeutics-coo-cfo-director-125921228.html

Money where his mouth is.

Looks like we'll need full fda approval now to pull back this fall.

Fingers crossed 🤞

Https://finance.yahoo.com/sectors/healthcare/articles/smmt-stock-surges-overnight-cancer-042504350.html

Https://finance.yahoo.com/sectors/healthcare/articles/ivonescimab-chemotherapy-demonstrated-statistically-significant-130600157.html

Https://finance.yahoo.com/sectors/healthcare/articles/encouraging-global-phase-ii-ivonescimab-120000128.html

Missed this before.

https://finance.yahoo.com/quote/SMMT/

Looks like the early data review our drug didn't come up to expeditions at this stage. Kinda an own goal. So we will have to wait until end of year full review.

As for a placing, 30 mill shares would get you close to half a billion.

Https://finance.yahoo.com/sectors/healthcare/articles/summit-therapeutics-reports-financial-results-203200813.html

All well bar burning through cash .

Probably a raise coming hence market reaction.

Need to finance it through testing and market eventually.

Https://finance.yahoo.com/sectors/healthcare/articles/ivonescimab-receives-major-recommendations-across-080700330.html

In China but all positive.

Yes indeed EP .

And profit taking today looks like.

Back to normal, some spike.

Wondering is news leaking somewhere.

Maybe just anticipation on upcoming news.

This news due before mid year 2026.

Summit Therapeutics has several key milestones and data readouts anticipated for Q2 2026 (April–June):

​HARMONi-3 Interim Analysis: The company expects to conduct an interim analysis for Progression-Free Survival (PFS) in the HARMONi-3 trial (squamous cohort) during the second quarter of 2026.

​New Trial Initiation: A Phase III study (ILLUMINE) for patients with head and neck squamous cell carcinoma is expected to begin enrollment and dose its first patient in early Q2 2026.

​GSK Collaboration: Clinical trials evaluating Ivonescimab in combination with GSK’s B7-H3 antibody-drug conjugate are scheduled to begin in mid-2026.

Help from AI

The FDA is currently reviewing Summit Therapeutics' drug, ivonescimab (SMT112), with a decision expected by November 14, 2026.

​The likelihood of approval appears strong based on current clinical evidence and regulatory status:

​Positive Phase III Data: In the HARMONi-A trial, ivonescimab significantly improved both progression-free survival (6.8 vs. 4.4 months) and overall survival (16.8 vs. 14.1 months) compared to chemotherapy alone in patients with lung cancer.

​Regulatory Milestone: The FDA has already accepted the Biologics License Application (BLA) for filing, which indicates the submission is complete enough to merit a full review.

​Fast Track Designation: The drug holds Fast Track status, suggesting the FDA recognizes its potential to address an unmet medical need.

​Prior Success: Ivonescimab is already approved in China, providing a foundation of real-world safety and efficacy data, though the FDA requires its own rigorous review of global trial data.

​Historically, drugs that reach the BLA stage have a roughly 90% approval rate, provided no major safety or manufacturing issues arise during the review process.

Getting up in the 20ts again , has legs the last week .

Fda outcome getting closer now too.

Good to see.

All about fda now

Fingers crossed

Https://finance.yahoo.com/sectors/healthcare/articles/ivonescimab-shows-quality-life-benefits-094000656.html

It all helps

https://finance.yahoo.com/sectors/healthcare/articles/summit-therapeutics-smmt-6-9-050337202.html

If we get fda approval late this year we will see a steady gain from then.

Thought they was two good rns.

Odd reaction from market early doors.

Might be looking for shares on a shake .

On we go.

Https://finance.yahoo.com/news/summit-therapeutics-announces-submission-biologics-110000923.html